Article PDF
References
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53:1937–1942
Peila R, Rodriguez BL, Launer LI. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002; 51:1256–1262
Ryan CM. Diabetes, aging, and cognitive decline. Neurobiol Aging 2005; 26 (Suppl.1): 21–25
Hassing LB, Hofer SM, Nilsson SE et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age and Ageing 2004; 33 (4): 355–61
Xu W, Caracciolo B, Wang H-X et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010; 59:2928–2935
Strachan MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997; 20 (3):438–45
Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 2012; 42: 484–491
Li J, Shao YH, Gong YP, Lu YH, Liu Y, Li CL. Diabetes mellitus and dementia–a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014; 18:1778–1789
Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 2005; 48:2460–2469
Chatterjee S, Peters SAE, Woodward M et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 2016; 39:300–307
Ravona-Springer R, Heymann A, Schmeidler J et al. Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. Plos One 2014; 9(6): e97384
Cui X, Amir A, Manor BD et al. Multi-scale glycemic variability: a link to gray matter atrophy and cognitive decline in type 2 diabetes. Plos One 2014; 9(1): e86284
Yaffe K, Falvey C, Hamilton N. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol. 2012 Sep;69(9):1170–5
Exalto LG, Biessels GJ, Karter AJ et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol 2013: 1(3): 183–190
Munshi MN. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 2017; 40: 461–467
Brands AM, Biessels GJ, de Haan et al. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005; 8: 726–735
T Li W, Huang E, Gao S. Type 1 Diabetes Mellitus and Cognitive Impairments: A Systematic Review. J Alzheimers Dis. 2017;57(1):29–36.
Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocrine Rev 2008; 29(4): 494–511
Yaffe K, Blackwell T, Whitmer RA et al. Glycosylated haemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006; 10: 293–5
Lehtisalo J, Lindstrom J, Ngandu T et al. Diabetes, glycaemia, and cognition–a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes Metab Res rev 2016; 32(1): 102–110
Sridhar GR, Lakshmi G, Nagamani G. Emerging links between type 2 diabetes and Alzheimer’s disease. World J Diabetes 2015 6(5): 744–751
Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s Disease. Med Hypotheses 2007; 69:1272–1276
Li W, Huang E. An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia. J Alzheimers Dis. 2016 May 3;53(2):393–402
Wrighten SA, Piroli GG, Grillo CA, Reagan LP. A look inside the diabetic brain: contributors to diabetes-induced brain aging. Biochim Biophys Acta 2009; 1792 (5): 444–453
Zhou X, Zhang J, Chen Y et al. Aggravated cognitive and brain functional impairment in mild cognitive impairment patients with type 2 diabetes: a resting state functional MRI study. J Alzheimers Dis 2014; 41(3): 925–35
Cui Y, Jiao Y, Chen YC et al. Altered spontaneous brain activity in type 2 diabetes: a resting-state functional MRI study. Diabetes 2014; 63(2): 749–60
Prince M1, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013 Jan;9(1):63–75.e2. doi: 10.1016/j.jalz.2012.11.007.
World Health Organisation. Diabetes: Global fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/
Sinclair AJ, Hillson R, Bayer AJ; National Expert Working Group. Diabetes and dementia in older people: a Best Clinical Practice Statement by a multidisciplinary National Expert Working Group. Diabet Med 2014; 31(9): 1024–31
Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type diabetes in older people. Diabetes Res Clin Pract 2014; 103(3): 538–40
Mehta HB, Mehta V, Goodwin JS. Association of hypoglycaemia with subsequent dementia in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2017; 7298): 1110–1116
Sullivan MD, Katon WJ, Lovato LC et al. Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry 2012; 70(10)1041–7
Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA. Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study. Arch Gen Psychiatry 2012; 69(4): 410–17
Abdelhafiz AH, McNicholas E, Sinclair AJ. Hypoglycemia, frailty and dementia in older people with diabetes: reciprocal relations and clinical implications. J Diabetes Complications 2016; 30(8): 1548–1554
Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract 2000; 50: 203–212
Bunn F, Goodman C, Jones PR et al. What works for whom in the management of diabetes in people living with dementia: a realist review. BMC Med 2017; 15(1): 141
García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P. Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer’s disease? Rev Neurol. 2014 Dec 1;59(11):517–24.
Liu J, Wang LN, Jia JP. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer’s disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. Drugs Aging. 2015 Jan;32(1):57–65
Galimberti D1, Scarpini E1. Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2017 Jan;26(1):97–101.. Epub 2016 Dec4.
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014 Feb;14:81–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sinclair, A.J., Vellas, B. Diabetes Mellitus and Cognitive Decline – Prevention Should Not Be Delayed!. J Prev Alzheimers Dis 5, 95–97 (2018). https://doi.org/10.14283/jpad.2018.9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14283/jpad.2018.9